Outset Medical (NASDAQ:OM) CFO Renee Gaeta Sells 4,543 Shares of Stock

Key Points

• CFO Renee Gaeta sold 4,543 Outset Medical shares at an average price of $4.39, generating approximately $19,944. The sale covered tax-withholding obligations, leaving her with 180,840 shares.
• Outset Medical shares fell to $4.18, while the company reported a quarterly loss of $0.80 per share, missing estimates, despite revenue of $31.64 million exceeding forecasts.
• Analysts have a consensus “Hold” rating and a $10.00 price target, with three Buy ratings, one Hold, and one Sell rating.

Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CFO Renee Gaeta sold 4,543 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $4.39, for a total value of $19,943.77. Following the transaction, the chief financial officer owned 180,840 shares of the company's stock, valued at approximately $793,887.60. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Renee Gaeta also recently made the following trade(s):

• On Wednesday, June 3rd, Renee Gaeta sold 17,672 shares of Outset Medical stock. The shares were sold at an average price of $4.94, for a total transaction of $87,299.68.

Outset Medical Stock Performance

Shares of NASDAQ OM traded down $0.33 during midday trading on Tuesday, hitting $4.18. 143,860 shares of the company's stock were exchanged, compared to its average volume of 407,222. Outset Medical, Inc. has a twelve month low of $3.00 and a twelve month high of $16.16. The firm has a market cap of $78.57 million, a P/E ratio of -1.02 and a beta of 1.96. The stock's 50 day moving average price is $4.58 and its 200-day moving average price is $4.24. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11.

Outset Medical (NASDAQ:OM - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The company had revenue of $31.64 million for the quarter, compared to analyst estimates of $28.97 million. Equities research analysts anticipate that Outset Medical, Inc. will post -3.9 EPS for the current year.

Hedge Funds Weigh In On Outset Medical

Several institutional investors and hedge funds have recently modified their holdings of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical in the fourth quarter worth approximately $29,000. Legal & General Group Plc acquired a new stake in Outset Medical in the second quarter valued at approximately $34,000. BNP Paribas Financial Markets grew its position in Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company's stock worth $40,000 after acquiring an additional 2,034 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Outset Medical in the fourth quarter worth approximately $46,000. Finally, HRT Financial LP acquired a new position in shares of Outset Medical during the 4th quarter worth $58,000.

Analysts Set New Price Targets

OM has been the topic of several research reports. TD Cowen reaffirmed a "buy" rating on shares of Outset Medical in a report on Friday, May 8th. Weiss Ratings upgraded Outset Medical from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Finally, Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Outset Medical currently has an average rating of "Hold" and a consensus target price of $10.00.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source